Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $123.22 Average PT from Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been assigned an average rating of “Hold” from the twenty analysts that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $123.22.

Several research analysts recently issued reports on ZBH shares. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Truist Financial raised their price objective on shares of Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a research note on Friday, November 1st. Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. BTIG Research dropped their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research note on Monday, September 16th.

Zimmer Biomet Trading Up 1.7 %

ZBH opened at $110.23 on Friday. The stock has a market cap of $21.94 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.99 and a beta of 1.02. Zimmer Biomet has a twelve month low of $101.47 and a twelve month high of $133.90. The company has a fifty day moving average of $106.79 and a 200-day moving average of $109.78. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.65 earnings per share. On average, sell-side analysts predict that Zimmer Biomet will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

Institutional Trading of Zimmer Biomet

A number of large investors have recently added to or reduced their stakes in ZBH. Toronto Dominion Bank increased its stake in shares of Zimmer Biomet by 14.5% in the third quarter. Toronto Dominion Bank now owns 68,747 shares of the medical equipment provider’s stock worth $7,421,000 after purchasing an additional 8,710 shares in the last quarter. Neo Ivy Capital Management purchased a new position in shares of Zimmer Biomet in the third quarter worth about $150,000. Brown Financial Advisors increased its stake in shares of Zimmer Biomet by 16.6% in the third quarter. Brown Financial Advisors now owns 9,566 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,361 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares in the last quarter. Finally, M&T Bank Corp increased its stake in shares of Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after purchasing an additional 8,709 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.